BPC-157 Protects Against Heart Attack Damage and Multi-Organ Failure in Rats

Rats received BPC-157 (10 ng/kg or 10 µg/kg IP), L-NAME (NOS blocker, 5 mg/kg IP), and L-arginine (NO precursor, 200 mg/kg IP) alone or in combination, either 30 min before or 5 min after isoprenaline (75 or 150 mg/kg SC). Myocardial infarction (single dose) and reinfarction (doses at 0h and 24h) models were used. Assessment included cardiac biomarkers, gross and histological examination, ECG, echocardiography, oxidative stress parameters, vascular pressure measurements, and gene expression analysis.

Heart attacks cause irreversible damage within minutes, and current treatments focus on restoring blood flow rather than directly protecting heart tissue. BPC-157's ability to reduce infarct size, preserve cardiac function, and prevent multi-organ complications in this model suggests potential as a cardioprotective agent. The finding that it worked even when given after the heart attack onset is particularly relevant for therapeutic application.

BPC-157 continues to accumulate preclinical evidence across multiple organ systems. This cardiac study is notable because it addresses not just local heart damage but the systemic cascade of multi-organ failure that follows severe cardiac events. The peptide's ability to modulate NO system function and vascular pressures suggests mechanisms that could be relevant to multiple cardiovascular conditions, though human studies remain absent.

This is an animal study using a chemical model of myocardial infarction (isoprenaline), which differs from the coronary artery blockage that causes most human heart attacks. No human data exist for BPC-157 in cardiac settings. The study comes from the Sikiric group, which produces the majority of BPC-157 research, limiting independent replication. Specific sample sizes per group and detailed statistical analyses are not provided in the abstract. The isoprenaline model primarily causes subendocardial necrosis rather than transmural infarction.